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ABSTRACT
This retrospective study of 251 lung transplant patients aimed to determine the prevalence, clinical
presentation and mortality of Aspergillus infection in order to deﬁne speciﬁc risk factors and to
compare survival in patients with and without infection. Aspergillus was isolated from 86 (33%)
cases, which involved colonisation (n = 50), tracheobronchial lesions (n = 17) or invasive aspergil-
losis (n = 19). Overall, aspergillosis had an impact on survival (p < 0.05); in fact the 5-year mortality
rate was substantially higher in single lung transplant recipients with bronchial anastomotic
infection, and in those with late-onset infections and chronic rejection. A signiﬁcant association
(p < 0.05) was found between acute rejection and the time at which fungal infection was diagnosed.
Aspergillus infection was not related to cytomegalovirus infection or treatment with corticosteroids.
The mortality rate for invasive infections was 78% and was related to survival (p < 0.0001);
invasive aspergillosis was also associated with chronic rejection (p < 0.05), but not with high
corticosteroid doses (p 0.49) or use of tacrolimus (p 0.73). In conclusion, Aspergillus infection was
associated with a reduction in the 5-year survival rate of lung transplant recipients, and this was
particularly true for patients infected with the invasive forms and for patients with single lung
transplants, bronchial anastomotic infection and chronic rejection. Isolation of Aspergillus spp. from
respiratory samples preceded acute rejection, and may be a marker of graft dysfunction and ⁄ or
airway inﬂammation. Close monitoring, or even pre-emptive antifungal therapy, is recommended
for patients with chronic rejection or bronchial airway mechanical abnormalities and persistent
Aspergillus colonisation.
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INTRODUCTION
Aspergillus is a widely distributed ﬁlamentous
fungus with branched septate hyphae. Isolation of
Aspergillus from lung transplant recipients may
occur following colonisation, tracheobronchitis,
invasive pulmonary aspergillosis or disseminated
disease [1–5]. Although the incidence of Aspergil-
lus infection in lung transplant patients is lower
than that of infections caused by bacteria and
viruses, Aspergillus causes a similar or even higher
mortality rate for several reasons: the difﬁculty in
achieving an early diagnosis; the lack of effective
treatment for infections caused by ﬁlamentous
fungi; the toxicity associated with interactions of
antifungal agents with immunosuppressive
drugs; the few available data on the effectiveness
of antifungal prophylaxis; and, ﬁnally, the
reduced level of immunosuppression that may
lead eventually to graft loss. Fungal infections
occur in 15–35% of patients following lung trans-
plantation. Many factors may predispose to fungal
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infections in lung transplant patients, including
pre-operative chronic lung disease, Aspergillus
colonisation, lung rejection, enhanced immuno-
suppression, cytomegalovirus (CMV) infection
and the type of antifungal agent used [3,6–8].
Since there are many controversial issues
regarding the management of aspergillosis in
lung transplant recipients, the present study
aimed to determine the prevalence, clinical pres-
entation and mortality of fungal infections caused
by Aspergillus in lung transplant recipients. The
possible association with speciﬁc risk factors
(such as acute and chronic rejection, corticosteroid
dose, CMV infection and type of immunosup-
pression) was also evaluated. An additional ana-




All patients in the lung and heart–lung transplantation
programme of the Hospital Universitario La Fe (Valencia)
from January 1991 to January 2004 were included in this study.
Information on fungal infection was obtained from the clinical
records and computer databases of the Lung Transplant Unit
and the Department of Microbiology of the hospital.
Criteria and deﬁnitions
For the purposes of this study, the different forms of
Aspergillus infection were deﬁned as follows [2,3]:
1. Aspergillus airway colonisation: patients with Aspergillus
cultured from the airway specimens in the absence of
invasive aspergillosis or tracheobronchitis.
2. Tracheobronchial aspergillosis or anastomotic infections:
isolation of Aspergillus in culture with histopathological
evidence of tissue invasion or necrosis, ulceration or
pseudomembranes on bronchoscopy.
3. Invasive pulmonary aspergillosis: invasive fungal infections
of the lung caused by Aspergillus spp., with clinical,
radiological and ⁄ or histological ﬁndings of pulmonary
tissue invasion by Aspergillus, together with isolation of
the fungus from respiratory samples. Invasive aspergillosis
was considered to be disseminated if the infection was
documented histopathologically at two or more non-conti-
guous organ sites.
4. Opportunistic invasive aspergillosis: diagnosed with
reference to the standardised criteria and deﬁnitions
formulated by the Invasive Fungal Infections Cooperative
Group (IFICG) of the European Organization for Research
and Treatment of Cancer (EORTC) in conjunction with
members of the Mycoses Study Group (MSG) of the
National Institute of Allergy and Infectious Diseases
(NIAID) [9].
Acute rejection, chronic rejection or bronchiolitis obliterans
syndrome were deﬁned according to the international classi-
ﬁcation of the Lung Rejection Study Group [10].
Lung transplant protocols: immunosuppression and
prophylactic measures
The immunosuppressive regimen consisted of a combination
of prednisone, azathioprine and cyclosporine. Induction ther-
apy was used only in the ﬁrst 20 cases and in the last three
(anti-thymocyte globulin or anti-interleukin-2 receptor anti-
bodies). Rejection episodes were treated with methylpredn-
isolone pulse therapy (1 g ⁄day for 3 days). In cases of
recurrent or refractory rejection episodes, cyclosporine was
replaced by tacrolimus, and azathioprine by mycophenolate;
six cases were treated with OKT3.
Prophylaxis against CMV, fungi and Pneumocystis carinii
infection was given to all patients as described previously [11].
The antifungal prophylactic protocol comprised ﬂuconazole
(200 mg ⁄day), except following the isolation of Aspergillus,
when the treatment was changed to itraconazole (200–
400 mg ⁄day) and nebulised amphotericin B (0.2 mg ⁄kg ⁄ 8 h)
during the ﬁrst month after transplantation, followed by lower
doses of nebulised amphotericin B (< 0.5 mg ⁄ kg ⁄day) until
months 3–6 after transplant.
Antifungal treatment regimens
Airway colonisation within 6 months of transplantation was
treated with amphotericin B aerosols and oral itraconazole
until the fungus was eradicated. If Aspergillus was detected
> 6 months after transplantation, only nebulised amphotericin
B (< 0.5 mg ⁄ kg ⁄day) was administered. For Aspergillus trache-
obronchitis, combined treatment with nebulised amphotericin
B and itraconazole was used to eradicate the fungus. However,
if signiﬁcant ulcerations were present, intravenous therapy
with lipid formulations of amphotericin B (3 mg ⁄kg ⁄day) or
caspofungin was started, with a switch to itraconazole or
voriconazole after treatment for 4 weeks (both of these drugs
have been introduced in the last 2 years). If invasive pulmon-
ary aspergillosis was diagnosed, initial treatment consisted of
a lipid formulation of amphotericin by the intravenous route
(dose 5 mg ⁄ kg ⁄day) or caspofungin, sometimes combined
with voriconazole plus high doses of nebulised amphotericin B,
until there was a clear clinical improvement in the patient’s
condition.
Follow-up
Chest X-rays, serum chemistry (glucose, kidney and liver
function tests), a complete blood count and a measurement
of blood levels of immunosuppressive drugs were per-
formed daily during the ﬁrst two post-operative weeks, and
every 2–3 days thereafter until discharge. A high-resolution
computerised tomography scan and lung function tests were
performed after 1 month. In addition, sputum samples were
cultured for bacteria and fungi every 5 days during the ﬁrst
month, every 3 months thereafter, and whenever respiratory
symptoms were noted. Microbiological tests for CMV in
blood (pp65 CMV antigenaemia) and respiratory (shell vial
culture) samples were performed every 2 weeks during the
ﬁrst month, monthly up to the third month after transplant,
and every 3 months thereafter, or if clinical or radiological
signs were evident. Surveillance bronchoscopy, with micro-
biological studies of bronchoalveolar lavage samples and
transbronchial biopsies, was performed 0, 2, 15, 30 and
90 days after transplantation, and if considered necessary for
clinical reasons. After the ﬁrst 3 months post-transplant,
360 Clinical Microbiology and Infection, Volume 11 Number 5, May 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 359–365
sputum cultures for epidemiological surveillance were
obtained every 2 months. Aspergillus spp. were identiﬁed
by morphological characteristics.
Statistical analysis
The Fisher Exact test was used to compare categorical variables
such as Aspergillus infection (colonisation, airway lesion, inva-
sive forms), rejection (acute or chronic), CMV infection, use of
corticosteroids and immunosuppressive drugs. Simple regres-
sion and the coefﬁcient of determinationwere applied to analyse
continuous variables as a temporal association between fungal
infection and acute rejection or immunosuppressants. Survival
rates were calculated by the Kaplan–Meier method and com-
pared with the log-rank test. The alpha level of signiﬁcance was
set at p < 0.05.
RESULTS
In total, 251 lung transplants were performed
during the 13-year study period. Of these, 186
were bilateral lung, 41 single lung and 19 heart–
lung transplants.
Prevalence of aspergillosis and clinical
presentation
Eighty-six cases of aspergillosis were diagnosed
(a prevalence of 33%), comprising 50 males and
36 females, with a mean age of 40 ± 6 years. The
main indications for transplantation in patients
with aspergillosis were pulmonary emphysema
(29%), pulmonary ﬁbrosis (28%), cystic ﬁbrosis
(25%), bronchiectasis (11%), primary pulmonary
hypertension (5%) and lymphangioleiomyomato-
sis (3%).
Colonisation by Aspergillus spp. occurred in
50 (20%) patients, involving Aspergillus fumiga-
tus (59%), Aspergillus ﬂavus (35%), Aspergillus
niger (4%), and unidentiﬁed Aspergillus spp.
(2%). Tracheobronchitis caused by Aspergillus
spp. occurred in 17 (6%) cases (Table 1) and
invasive infection in 19 (8%) cases (Table 2);
most of the latter cases involved invasive pul-
monary aspergillosis. Six cases involved dissem-
inated infection; in two of these, the initial
symptoms were an epidural abscess and a hip
arthritis associated with aortic endocarditis.
A. fumigatus was identiﬁed as the sole pathogen
in all invasive cases, with the exception of one
pulmonary infection in which Scedosporium apio-
spermun was present simultaneously. In 13 of
the 19 cases, cultures of respiratory samples
were sporadically or persistently positive for
A. fumigatus for several months before the onset
of invasive infection.
The time of onset was related strongly to the
clinical form of aspergillosis. All tracheobronch-
itis or bronchial anastomotic infections occurred
within 3 months of transplantation. In contrast,
invasive or disseminated aspergillosis occurred
signiﬁcantly later (33.7 ± 19.6 months post-trans-
plantation). The early invasive pulmonary forms
(Table 2) occurred simultaneously with tracheo-
bronchial Aspergillus infection.
Table 1. Characteristics of patients
with airway lesions associated with
Aspergillus spp.
No. Diagnosis Type Airway lesion Site Treatment FEV1 (%)
Survival and
outcome
1 CF BL Bronchial stenosis Bilateral Prosthesis 80 8 years
2 CF BL Pseudomembrane Bilateral – – Died
3 LAM BL Bronchial stenosis LMB Prosthesis 83 4 years
4 Emphysema SL Pseudomembrane
Bronchial stenosis
LMB – – Died
5 CF BL ﬁstula RMB Laser 80 6 years
6 CF BL Ulcers
Bronchial stenosis
LMB Prosthesis 60 4 years
7 CF BL Bronchial stenosis LMB Dilatation 60 7 years
8 Emphysema SL Bronchial stenosis RMB Dilatation 60 Died
3 years
9 CF BL Bronchial stenosis LMB Dilatation 80 2 years
10 CF BL Bronchial stenosis RMB – 80 2 years
11 Emphysema SL Bronchial stenosis LMB Dilatation 50 2 years
12 Bronchiectasis BL Bronchial stenosis LMB Prosthesis 70 1 years
13 Bronchiectasis BL Bronchial stenosis LMB Dilatation 80 1 years
14 Emphysema SL Bronchial stenosis RMB Dilatation 50 Died
1 year
15 Emphysema SL Bronchial stenosis RMB Dilatation 40 Died
6 months
16 CF BL Bronchial stenosis RMB – 60 5 months
17 CF BL Bronchial stenosis RMB Dilatation 70 4 months
Patients 2 and 7 were colonised by Aspergillus spp. before lung transplantation.
All cases were diagnosed within 2 months of transplantation. All were treated with nebulised amphotericin and
oral itraconazole. Cases 1, 2, 4 and 5 also received liposomal amphotericin; cases 16 and 17 received caspofungin.
CF, cystic ﬁbrosis; LAM, lymphangioleiomyomatosis; LMB, left main bronchus; RMB, right main bronchus; SL,
single lung; BL, bilateral lung; FEV1, forced expiratory volume in 1 s.
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Anastomotic infections were found more
frequently in cystic ﬁbrosis patients. Among the
patients with airway problems, those with
emphysema had the worse prognosis; indeed, in
four of the ﬁve cases of emphysema, the initial
Aspergillus infection progressed to a pulmonary
invasive form and the patient died (Table 1). All
four of these cases involved single lung trans-
plants, as well as persistent Aspergillus colonisa-
tion and associated chronic rejection.
Aspergillus colonisation was detected within
3 months of transplantation in 56% of patients
and > 12 months after transplantation in 20% of
patients. All of the patients who developed
invasive infections yielded positive cultures,
except for one case (diagnosed following
autopsy). The time from the ﬁrst isolation of
Aspergillus spp. to the development of invasive
infection varied from 1 to 7 months (mean,
4 months).
Risk factors
Typically, Aspergillus was detected in respiratory
samples 1.8 ± 4 months preceding an acute rejec-
tion episode. There was a signiﬁcant association
(p < 0.05) between the time at which Aspergillus
spp. were ﬁrst isolated and the time of diagnosis
of acute rejection (R2 = 0.92), administration of
tacrolimus (R2 = 0.67) and administration of
mycophenolate (R2 = 0.44). There was no signiﬁ-
cant association with CMV infection or cortico-
steroid doses. The incidence of acute rejection was
similar (p > 0.05) between the three different
forms of Aspergillus infection (61% colonisation,
63% airway infections and 70% invasive infec-
tions). There was no correlation of invasive
disease with CMV infection (p 0.40), high corti-
costeroid doses (p 0.49) or the use of tacrolimus
(p 0.73); the only signiﬁcant association was
found with chronic rejection (p < 0.05). Bronchio-
litis obliterans syndrome was diagnosed in 87%
of invasive cases, compared to 44% of colonised
cases and 57% of those with airway infection.
Survival
The mortality of Aspergillus infection was 14% in
cases with tracheobronchitis, 28% in colonised
cases, and 78% in cases with invasive infections
(p < 0.05). The mortality caused by invasive
fungal infections was related directly to Aspergil-
lus spp. Five patients died within 6 months of
transplantation, while the remainder died after a
Table 2. Characteristics of patients





1 P, A, EB, End BL 3 PAC, EB Amphotericin B Died
2 P BL 26 CR Amphotericin B IV Died
3 P, EA BL 17 CR Amphotericin B Died
4 P, LM SL 12 CR Amphotericin B Died
5 P, EB SL 2 EB Amphotericin B Died
6 P, EB BL 1 EB Amphotericin B Alive
7 P BL 12 CR – Died
8 P BL 48 CR Amphotericin B IV Died
9 P, B BL 12 CMV, AR – Died
10 P BL 12 – Amphotericin B Alive
11 P, B SL 34 CR Amphotericin B IV +
itraconazole
Died
12 P SL 36 CR Amphotericin B IV +
caspofungin
Died
13 P, A SL 30 EB, CR Amphotericin B IV +
itraconazole
Died
14 P BL 48 EB, CR Caspofungin +
voriconazole
Alive
15 P, PSAb BL 60 CR Amphotericin B IV +
itraconazole
Died
16 P SL 6 EB, CR Amphotericin B IV
itraconazole
Died
17 P HL 34 CR Amphotericin B IV +
itraconazole
Died
18 P BL 72 PAC, CR Caspofungin +
voriconazole
Alive
19 P BL 74 CR Caspofungin +
voriconazole
Alive
P, pneumonia; End, endocarditis; A, arthritis; EA, epidural abscess; EB, endobronchial lesion; PAC, previous
airway colonisation; B, brain; LM, leg mycetome; CR, chronic rejection; PSAb, psoas abscess; SL, single lung; BL,
bilateral lung; HL, heart–lung; IV, intravenous; CMV, cytomegalovirus..
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follow-up period of > 1 year. In two cases, the
invasive fungal infection was diagnosed at aut-
opsy.
Actuarial survival in patients with any form of
Aspergillus infection was 81%, 51% and 39% after
1, 3 and 5 years, respectively. The 5-year survival
rate was lower (p < 0.05) when compared to
patients without infection (Fig. 1). Invasive infec-
tions were related strongly to survival
(p < 0.0001) (Fig. 2).
DISCUSSION
Infection with Aspergillus poses signiﬁcant prob-
lems for lung transplant patients, with high rates
of morbidity and mortality [2,3,7]. Moreover,
there is no established and uniform approach to
prophylactic regimens and antifungal therapy
[8,11–14], and simple colonisation has been asso-
ciated with progression to endobronchial lesions
and invasive infection [3,15,16]. Management
decisions are difﬁcult when Aspergillus is isolated
from respiratory samples, particularly in the
absence of respiratory symptoms. Furthermore,
the current and potential pathogenicity of these
fungi are unknown, although it has been found
that patients colonised with Aspergillus and other
fungi have signiﬁcantly greater neutrophil counts
in bronchoalveolar ﬂuid, a ﬁnding that is associ-
ated with a poor outcome in lung transplant
recipients [8,17].
Given these unanswered questions regarding
the management of aspergillosis in lung trans-
plant recipients, the present study aimed to
determine the prevalence, outcome and potential
risk factors in a large single-centre cohort. Asperg-
illuswas isolated from 33% of patients, but simple
isolation of Aspergillus did not affect overall
survival following lung transplantation. The fre-
quency and types of Aspergillus infection (airway
colonisation, tracheobronchitis and invasive pul-
monary aspergillosis), and the time to diagnosis,
were similar to those reported previously [4,14].
Interestingly, detection of Aspergillus in respirat-
ory samples preceded diagnosis of acute rejection
in a substantial proportion of patients, and could
be considered an early marker of possible inﬂam-
matory events in the airways that might promote
infection by Aspergillus or predispose to acute
rejection, in the same way that fungal infection
has been implicated in the development of chro-
nic rejection [17–19]. Pre- and post-transplant
colonisation and tracheobronchial aspergillosis
[2,6,7,16,20–22] have often been implicated in the
development of invasive infections. In the present
study, pre-transplant colonisation occurred in
only two cases, but six patients with invasive
fungal infection had a coexisting airway lesion
related to the fungus.
The present study established and conﬁrmed a
strong association between invasive infections
and chronic rejection. Thus, antifungal prophy-
laxis and ⁄ or pre-emptive therapy with antifungal
agents is recommended for patients with chronic
rejection and positive respiratory samples for
Aspergillus, even if no endobronchial involvement
or radiological signs are evident. Such treatment
should continue for at least 3 months, which is
Fig. 1. Actuarial survival in lung transplant recipients
from whom Aspergillus was isolated (log-rank test,
p < 0.05).
Fig. 2. Actuarial survival in lung transplant recipients
with invasive and non-invasive forms of aspergillosis (log-
rank test, p < 0.0001).
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the period over which colonisation has been
shown to precede disseminated infection [15].
In terms of clinical presentation, previous
studies have reported that 5.7% of patients with
a positive airway culture progress subsequently
to invasive infections [3], and that Aspergillus
colonisation may precede bronchial complications
by 8 weeks [16]. In addition, the present data
show a signiﬁcant increase of bronchial anasto-
motic infections in cystic ﬁbrosis patients colo-
nised previously with Aspergillus. An association
between fungal infections and airway anastomot-
ic lesions has also been reported [8,21–23]. In the
present series, nine of the 17 patients with airway
abnormalities were cystic ﬁbrosis patients, but
only two were colonised previously by Aspergil-
lus; one died from a disseminated form of asper-
gillosis, despite full antifungal therapy pre- and
post-lung transplant. The time required for devel-
opment of invasive Aspergillus infection was
clustered in two periods, i.e., either within the
ﬁrst 6 months post-lung transplant, despite
antifungal prophylaxis, or > 1 year following
transplant. Disseminated infections included
uncommon presentations, such as endocarditis,
with fewer than ten cases reported previously
[24], or a case of epidural abscess, which is a rare
complication in transplant recipients [25].
Invasive fungal infections occurred mainly in
patientswith chronic rejection, suggesting that pre-
emptive antifungal therapy should be started for
patients with bronchiolitis obliterans syndrome,
with clinical, radiological and microbiological
monitoring for early diagnosis and subsequent
treatment. Since Aspergillus infection may be a
marker of acute rejection, close monitoring of lung
function is recommended for asymptomatic pa-
tients from whom Aspergillus is detected in respir-
atory samples. A combination of caspofungin and
voriconazole may be optimal for the treatment of
invasive aspergillosis, and, in the present series, all
of the patients with invasive aspergillosis who
received this combination survived (Table 2). New
microbiological techniques for detection of galac-
tomannan antigen [26], or molecular methods,
such as PCR, may allow early detection of Asperg-
illus in blood or respiratory samples [27]. Early
microbiological diagnosis, in conjunction with
sequential high-resolution chest imaging tech-
niques, may change the management of invasive
pulmonary aspergillosis by facilitating both the
pre-emptive and the therapeutic approach.
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